admin – Page 3107 – Get News Story

Adam Blain, Founder of AAA Life Solutions, Shares a Smarter Approach to Retirement Planning in a TV Interview

Lansing, MI – Adam Blain, Founder of AAA Life Solutions, was recently featured on Fox 47’s The Morning Blend, where he shared his unique perspective on building retirement strategies that go beyond conventional planning. With a focus on security, control, and long-term tax efficiency, Blain helps clients craft retirement plans that reflect their values and financial goals.

In the interview, Blain emphasized the importance of thinking proactively about retirement. “It’s not just about how much you’ve saved—it’s about how you structure those savings to work for you in the most efficient way possible,” he explained. “Too many people underestimate the long-term impact of taxes and market risk. Our approach ensures that clients have the clarity and confidence they need to retire with purpose.”

Blain highlighted the key components of his approach: income stability, tax-advantaged strategies, and protection against market volatility. He also addressed a growing concern among retirees—outliving their money. By integrating indexed strategies and life insurance-based planning tools, AAA Life Solutions provides clients with tailored solutions that prioritize both growth and protection.

Through AAA Life Solutions, Blain takes a consultative approach, getting to know each client’s unique situation before recommending any financial tools or products. His goal is to educate and empower clients, helping them make informed decisions that align with their long-term retirement vision.

About Adam Blain and AAA Life Solutions:

Adam Blain founded AAA Life Solutions with a mission to simplify and strengthen retirement planning. With years of experience in the financial services industry, Adam specializes in helping individuals and families create holistic, tax-efficient retirement strategies that are built to withstand economic uncertainty. His firm is known for its integrity, client-first service, and a passion for helping people retire smarter, not harder.

Learn more: https://www.aaalifesolutions.com

Registered Representative and Investment Advisor Representative services offered through affiliated and licensed entities. AAA Life Solutions is an independent firm and not affiliated with Fox 47 or The Morning Blend. All Statements and opinions expressed are based upon information considered reliable, although it should not be relied upon as such. Any statements or opinions are subject to change without notice. Investments involve risk and unless otherwise stated are not guaranteed. Past performance cannot be used as an indicator to determine future results. Any strategies mentioned may not be suitable for everyone, information expressed does not take into account your specific situation or objectives and is not intended as recommendations appropriate for you. Before acting on any information mentioned, please consult with a qualified tax or investment advisor to determine if it is suitable for your specific situation. This program is designed to provide accurate and authoritative information with regard to subject covered. BWA Disclosure: Investment advisory services offered through Brookstone Wealth Advisors, LLC (BWA), a registered investment advisor and an affiliate of Brookstone Capital Management, LLC. BWA and AAA. Life Solutions are independent of each other. Insurance products and services are not offered through BWA but are offered and sold through individually licensed and appointed agents. Registered Investment Advisors and Investment Advisor Representatives act as fiduciaries for all of our investment management clients. We have an obligation to act in the best interests of our clients and to make full disclosure of any conflicts of interests. Please refer to our firm brochure, the ADV 2A item 4, for additional information.

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

E.E. Smith Alumni Sports Hall of Fame Inc. Announces 2025 Inductees and Special Team Honor

E.E. Smith Alumni Sports Hall of Fame Inc

Join us for an unforgettable evening as we honor a distinguished group of E.E. Smith alumni whose achievements have made a lasting impact on our community, school, and the world of athletics. We will also pay tribute to the legendary 1981 North Carolina 4A Girls Track Team, celebrating their historic state championship victory.

Fayetteville, NC – The E.E. Smith Alumni Sports Hall of Fame Inc., proudly powered by Jerome Scott The Insurance Guy and Covington Insurance LLC, is thrilled to announce the Class of 2025 Inductees and a special celebration of athletic excellence at this year’s Hall of Fame Induction Ceremony.

Join us for an unforgettable evening as we honor a distinguished group of E.E. Smith alumni whose achievements have made a lasting impact on our community, school, and the world of athletics. We will also pay tribute to the legendary 1981 North Carolina 4A Girls Track Team, celebrating their historic state championship victory.

Event Details:

Date: Sunday, May 25, 2025

Time: 5:00 PM

Location: Crown Expo Center, 1960 Coliseum Dr, Fayetteville, NC

Class of 2025 Inductees:

• Darius Purcell – Class of 2008

• Ben Major – Class of 1979

• Kanetra Queen – Class of 2000

• Ira Cheatham – Class of 1983

• Stan Callender – Class of 1991

• Joseph Vaughn – Class of 1977

• Selena Washington – Class of 1975

• Connie Boykin – Class of 1960

• Charles “Billy” Davis – Class of 1962

• Coach Martin “Rick” Rickman – Legendary Coach

• Tommy McAllister – Class of 1965

This celebration will be a night filled with recognition, inspiration, and reconnection among alumni, families, and supporters of E.E. Smith High School. From athletic triumphs to community leadership, the stories of our inductees exemplify the excellence and pride of the Golden Bulls legacy.

For media inquiries, sponsorship opportunities, or to purchase tickets, please contact ShaDonna “Mo” McPhaul at (910) 574-3346 or shadonnamack@me.com.

Let’s come together as a community to honor the past, inspire the future, and celebrate our Hall of Fame family. We look forward to seeing you there!

E.E. Smith Alumni Sports Hall of Fame, Inc.

Powered by Jerome Scott The Insurance Guy and Covington Insurance LLC

Preserving Legacy. Celebrating Excellence. Inspiring Generations.

Contact:

ShaDonna “Mo” McPhaul

Public Relations Director

E.E. Smith Alumni Sports Hall of Fame, Inc.

Phone: (910) 574-3346

Email: shadonnamack@me.com

Media Contact
Company Name: E.E. Smith Sports Hall of Fame
Contact Person: John Brown
Email: Send Email
Phone: 267 625 4464
Address:P.O. Box 3101
City: Fayetteville
State: NC
Country: United States
Website: Www.Eesmithsports.com

New Book “The Alien Apocalypse Where Do They Come From and Why are They Here?” Challenges Conventional Views on Gods, Aliens, and Extraterrestrials

Oklahoma City, OK, USA – June 2, 2025 – A provocative new book, “The Alien Apocalypse Where Do They Come From and Why are They Here?” by Frank Morin, delves into humanity’s fascination and fear surrounding the concepts of Gods, Aliens, and Extraterrestrials, proposing a controversial framework that distinguishes between these entities and links their presence to ancient history and biblical accounts. Published by LifeRich Publishing, this book challenges widely held beliefs and offers alternative explanations for phenomena ranging from UFOs to animal mutilations.

The author asserts a fundamental distinction often blurred in popular culture: Aliens and Extraterrestrials are NOT the same entities. According to the book, Angels are the true Aliens, originating from heaven, which is described as somewhere other than Earth. Angels are Celestial Entities, capable of possessing physical or nonphysical bodies and do not require a craft to travel. When using physical bodies on Earth, they are called Anakites.

In contrast, the entities commonly referred to as Extraterrestrials are identified as Hybrid Celestial children, also known as Nephilim in the Bible. These are the offspring of Angels (“sons of God”) and human women. Unlike Angels, Nephilim have physical bodies similar to their human mothers and DO require a craft (Unidentified Flying Object – UFO) for transportation. The book suggests that these Extraterrestrials have only existed for less than twenty thousand years, having been born when Angels procreated with human women.

Morin proposes that these Hybrid Celestial children and their mothers relocated from Earth to the dark side of the moon about eighteen thousand years ago when Angels foresaw a coming flood on Earth. Permanent, airtight facilities were constructed on the moon, which the author believes still exist. The book connects ancient advanced structures like those in Puma Punku, Bolivia, to these entities practicing building techniques for their lunar facilities. Other sites like the pyramids in Egypt and structures in Peru are also linked to the knowledge and technology of Nephilim and Angels.

The book reinterprets ancient myths and stories, suggesting they were human attempts to explain the superior intelligence and advanced technology demonstrated by Angels and their Hybrid children. Events and technology that humans couldn’t understand were often attributed to “gods” in antiquity, a role the author believes was played by these entities.

Modern sightings of UFOs are described as the crafts used by the Hybrid Celestial entities. These crafts possess capabilities far beyond human physics, such as making 90-degree turns and stopping midair. The book suggests that Nephilim have traveled to and colonized the moon, Mars (a colony since abandoned), and even the Sirius star cluster, utilizing technology like Vortex travel for long distances. They maintain communities on the moon and at the bottom of Earth’s oceans, often in large craft capable of maintaining an entire community.

A particularly startling claim in the book relates to animal mutilations, which the author posits are attempts by Nephilim to reproduce the process of creating milk without housing cows or horses. This need, he suggests, arose from their efforts to produce new infants and small children using human embryos, possibly acquired from abducted women, to replace Nephilim lost in accidents. The surgical precision of these mutilations indicates an advanced technology beyond human capability.

The book also touches on attempts by these entities to communicate with humans, citing incidents like the Bentwater, England event and Crop Circles as potential messages. Despite these attempts, the author notes that Extraterrestrials have often been met with fear and aggression from humans, who tend to fantasize them as dangerous creatures.

Drawing heavily on interpretations of the Bible, particularly Genesis, the author places the creation of different human types (Neanderthal humanoids, first creation Cro-Magnon, and Adam and Eve) within this narrative, suggesting that the beauty of Eve and her descendants attracted the Angels. The author also touches on the concept of humans themselves becoming Extraterrestrials upon traveling to the moon.

“The Alien Apocalypse Where Do They Come From and Why are They Here?” offers a unique perspective that intertwines biblical accounts, ancient mysteries, and modern UFO phenomena. The author suggests that governments, including the U.S., are likely aware of these entities and their technology, possibly engaging in reverse engineering since events like the 1947 Roswell crash.

About the Author:

Frank Morin is the author of “The Alien Apocalypse Where Do They Come From and Why are They Here?”. He dedicates the book to his son Thomas, whose encouragement motivated its completion. The views expressed in the book are solely those of the author and do not necessarily reflect the views of the publisher.

Frank Morin’s “The Alien Apocalypse Where Do They Come From and Why are They Here?” is available for order through all online platforms.

Paperback: 978-1-4897-0211-1

Ebook/Kindle: 978-1-4897-0212-8

Contact: Gary Davis | gary.davis@lighthouseliterary.us | (405) 953-8860 Ext. 104

Media Contact
Company Name: Lighthouse Literary
Contact Person: Gary Davis
Email: Send Email
Phone: 405-953-8860
Country: United States
Website: https://lighthouseliterary.us

Breaking the Fatigue Cycle – Katie Dean’s Newly Released Book is a Compassionate Guide to Navigating Chronic Fatigue Syndrome

Waitsfield, Vermont, USA – June 2, 2025 – Bioenergetic Health Coach and author Katie Dean has now released her new book, Finding the Energy to Thrive: Navigating the Maze of Life and Embracing Your Path to Wholeness. This is a highly transformative educational resource, offering an innovative approach to healing through nervous system repair and bioenergetics. The book not only presents a proven framework for Chronic Fatigue Syndrome (CFS) recovery, but it also shares the author’s inspiring personal journey of healing.

Finding the Energy to Thrive is a culmination of the author’s 20-year journey into researching every available treatment option for CFS. What began as a quest for personal recovery eventually turned into a complete roadmap for healing that has helped numerous people reclaim their lives. The analogy of navigating a hedge maze is central to the book’s theme, often comparing the CFS recovery process to hitting a dead end multiple times before finding the path through. The book sheds light on unresolved trauma and how it can cause nervous system disruption, which can result in a range of symptoms associated with CFS. It describes how, when traditional medicine is unable to provide answers, bioenergetic healing can open the door to a genuine, long-lasting recovery. Along with many other tried-and-true methods to protect the nervous system and guarantee a stable recovery, the author also presents the Four Levels of Creation model and helpful tools like the “Energy Saving Aid” for brain fog and enhanced clarity.

Katie Dean, PhD, is a Cambridge-educated historian turned bioenergetic health pioneer whose personal 20-year battle with Chronic Fatigue Syndrome (CFS) led to groundbreaking discoveries in energy medicine. After doctors declared her condition untreatable, the former London business strategist systematically decoded her recovery through advanced trauma work, nervous system repair, and bioenergetic healing—breakthroughs she now shares through her Find My Energy practice and the revolutionary Kolorlan System.

As an award-winning beading artist, her work has reached people worldwide, and she has published 30+ books on beadwork design. She is highly passionate about helping people reach their full potential through self-love. Her work continues to have a positive impact, whether through direct coaching or groundbreaking research for the betterment of society. Katie Dean is available for interviews.

Finding the Energy to Thrive: Navigating the Maze of Life and Embracing Your Path to Wholeness is now available on Amazon.com.

Book Preview:

https://www.amazon.co.uk/dp/B0F9HBK531

https://www.amazon.com/dp/B0F9HBK531

About Katie Dean: https://katiedean.co.uk

Media Contact
Company Name: Beyond Belief Publishing
Contact Person: Autumn Carlton
Email: Send Email
Phone: 310-823-2661
Country: United States
Website: https://www.amazon.com/dp/B0F9HBK531

National Institute of Public Safety Launches BSIS-Certified Security Guard Training Across Los Angeles County

New program offers flexible online, hybrid, and in-person options for those pursuing a Guard Card or security certification in Los Angeles County.

The National Institute of Public Safety (National IPS) has launched its California Bureau of Security and Investigative Services (BSIS)-certified security guard training programs throughout Los Angeles County. The rollout includes online, hybrid, and in-person learning options, offering new and existing security professionals greater access to the training needed to meet BSIS requirements.

The initiative aims to prepare individuals for careers in the security sector by delivering courses that meet state mandates for obtaining or renewing a California Guard Card. The programs respond to increasing demand across the region. Data from the California Employment Development Department projects a 7% growth in the Los Angeles County security industry by 2030, with thousands of job openings expected each year.

“Our mission is to make it easier than ever for people to access high-quality, BSIS-approved security guard training in Los Angeles,” a representative of National IPS said. “Whether someone is just beginning their career or looking to renew a license, we provide all the required BSIS courses on one accessible platform—available online, hybrid, or in person.”

The curriculum includes the 8-hour Powers to Arrest and Appropriate Use of Force course for new guards, a 32-hour continued training program to be completed within six months of employment, and the 8-hour annual refresher. These programs meet all California licensing requirements. Courses are delivered through an interactive platform designed to accommodate diverse learning styles, with features such as gamification and access across devices—ideal for working adults and those seeking career transitions.

National IPS also offers support for navigating state licensing processes, helping participants understand how to become a security guard in California and follow a clear certification path. Its BSIS license (ATG-2976) confirms its standing as an approved provider for those aiming to get a Guard Card in LA or complete Guard Card classes in LA County.

“We’re committed to supporting workforce development and public safety across the region—including in cities like Santa Clarita,” the representative said. “We aim to be the go-to option for anyone searching for BSIS training near me or how to become a security guard in Los Angeles County.”

With the program now available, National IPS serves those looking for Los Angeles security license training, security certification in Los Angeles County, or seeking to complete Guard Card online Los Angeles. The launch also helps answer growing interest in how to become a security guard in LA, how to become a security guard in Santa Clarita, and other nearby areas.

About the National Institute of Public Safety

The National Institute of Public Safety is a licensed provider of public safety and security training, offering online, hybrid, and in-person courses across California and additional U.S. states. Focused on regulatory compliance, job readiness, and career advancement, National IPS supports thousands of learners annually through its digital learning platform and training centers.

For more information, visit https://nationalips.com/california-state/.

Media Contact
Company Name: National Institute of Public Safety
Contact Person: Chase W.
Email: Send Email
Country: United States
Website: https://nationalips.com/california-state/

Acral Lentiginous Melanoma Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Acral Lentiginous Melanoma Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acral Lentiginous Melanoma pipeline landscape. It covers the Acral Lentiginous Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acral Lentiginous Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Acral Lentiginous Melanoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Acral Lentiginous Melanoma Pipeline Outlook

Key Takeaways from the Acral Lentiginous Melanoma Pipeline Report

In May 2025, Medicenna Therapeutics Inc. announced a Phase 1/2 dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
DelveInsight’s Acral Lentiginous Melanoma Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Acral Lentiginous Melanoma treatment.
The leading Acral Lentiginous Melanoma Companies such as Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
Promising Acral Lentiginous Melanoma Pipeline Therapies such as Pembrolizumab (KEYTRUDA®), MDNA11, Tebentafusp, IBI363, Imatinib, Nilotinib, Sunitinib and others.

Stay ahead with the most recent pipeline outlook for Acral Lentiginous Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acral Lentiginous Melanoma Treatment Drugs

Acral Lentiginous Melanoma Emerging Drugs Profile

MDNA11: Medicenna Therapeutics, Inc.

MDNA11 is a long-acting IL-2 Superkine that has been fused with human recombinant albumin, which increases its half-life and minimizes dosing requirements without sacrificing efficacy and safety. This Superkine has been designed to preferentially bind the IL-2 beta receptor (IL-2Rβ) on immune cells and to become a powerful switch for activating and proliferating the immune cells needed to fight cancer. It is being developed specifically as a therapeutic for various solid tumors, potentially in combination with other immunotherapies. MDNA11 has the ability to preferentially stimulate cancer-fighting NK cells and naive CD8 cells instead of immuno-suppressive regulatory T cells, by 80 and 200 fold, respectively, when compared to native IL-2. It does so by specifically binding to IL-2Rβ. and begins a cascade of events that overcomes the immune-suppressing effects of cancer and activates the cancer-killing immune cells – including cytotoxic T cells, naive T cells, and natural killer cells. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Acral Lentiginous Melanoma.

The Acral Lentiginous Melanoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Acral Lentiginous Melanoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acral Lentiginous Melanoma Treatment.
Acral Lentiginous Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acral Lentiginous Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acral Lentiginous Melanoma market

Explore groundbreaking therapies and clinical trials in the Acral Lentiginous Melanoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Acral Lentiginous Melanoma Drugs

Acral Lentiginous Melanoma Companies

Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.

Acral lentiginous melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Acral Lentiginous Melanoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Acral Lentiginous Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Acral Lentiginous Melanoma Market Drivers and Barriers

Scope of the Acral Lentiginous Melanoma Pipeline Report

Coverage- Global
Acral Lentiginous Melanoma Companies- Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
Acral Lentiginous Melanoma Pipeline Therapies- Pembrolizumab (KEYTRUDA®), MDNA11, Tebentafusp, IBI363, Imatinib, Nilotinib, Sunitinib and others.
Acral Lentiginous Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Acral Lentiginous Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Acral Lentiginous Melanoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Acral Lentiginous Melanoma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Acral lentiginous melanoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Acral lentiginous melanoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
IBI-310: Innovent Biologics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
MDNA11: Medicenna Therapeutics, Inc.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Acral lentiginous melanoma Key Companies
Acral lentiginous melanoma Key Products
Acral lentiginous melanoma- Unmet Needs
Acral lentiginous melanoma- Market Drivers and Barriers
Acral lentiginous melanoma- Future Perspectives and Conclusion
Acral lentiginous melanoma Analyst Views
Acral lentiginous melanoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acral Lentiginous Melanoma Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Adenoid Cystic Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid Cystic Carcinoma pipeline landscape. It covers the Adenoid Cystic Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adenoid Cystic Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Adenoid Cystic Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Adenoid Cystic Carcinoma Pipeline Outlook

Key Takeaways from the Adenoid Cystic Carcinoma Pipeline Report

In May 2025, OncoC4 Inc. announced a Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
DelveInsight’s Adenoid Cystic Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adenoid Cystic Carcinoma treatment.
The leading Adenoid Cystic Carcinoma Companies such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
Promising Adenoid Cystic Carcinoma Pipeline Therapies such as CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.

Stay ahead with the most recent pipeline outlook for Adenoid Cystic Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adenoid Cystic Carcinoma Treatment Drugs

Adenoid Cystic Carcinoma Emerging Drugs Profile

Rivoceranib : Elevar Therapeutics

Rivoceranib is the first small-molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name Apatinib in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib has been studied in over 1,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy. Clinical studies are underway in multiple tumor types including, gastric cancer, hepatocellular carcinoma (combo w/camrelizumab), adenoid cystic carcinoma, and colorectal cancer (combo w/Lonsurf®). Orphan drug designations for rivoceranib have been granted in gastric cancer (U.S., EU, and South Korea) in adenoid cystic carcinoma (U.S.), and hepatocellular carcinoma (U.S.).

Osugacestat: Ayala Pharmaceuticals

Ayala Pharmaceuticals investigational lead candidate (AL-101) is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in 2 ongoing Phase 2 trials. The ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with recurrent/metastatic triple negative breast cancer (R/M TNBC). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.

The Adenoid Cystic Carcinoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Adenoid Cystic Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adenoid Cystic Carcinoma Treatment.
Adenoid Cystic Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Adenoid Cystic Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adenoid Cystic Carcinoma market

Explore groundbreaking therapies and clinical trials in the Adenoid Cystic Carcinoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Adenoid Cystic Carcinoma Drugs

Adenoid Cystic Carcinoma Companies

Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.

Adenoid Cystic Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Adenoid Cystic Carcinoma Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Unveil the future of Adenoid Cystic Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Adenoid Cystic Carcinoma Market Drivers and Barriers

Scope of the Adenoid Cystic Carcinoma Pipeline Report

Coverage- Global
Adenoid Cystic Carcinoma Companies- Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
Adenoid Cystic Carcinoma Pipeline Therapies- CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.
Adenoid Cystic Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Adenoid Cystic Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Adenoid Cystic Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Adenoid Cystic Carcinoma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Adenoid Cystic Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Adenoid Cystic Carcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AL101: Ayala Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Adenoid Cystic Carcinoma Key Companies
Adenoid Cystic Carcinoma Key Products
Adenoid Cystic Carcinoma- Unmet Needs
Adenoid Cystic Carcinoma- Market Drivers and Barriers
Adenoid Cystic Carcinoma- Future Perspectives and Conclusion
Adenoid Cystic Carcinoma Analyst Views
Adenoid Cystic Carcinoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Advanced Melanoma Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Advanced Melanoma Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Advanced Melanoma pipeline landscape. It covers the Advanced Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Advanced Melanoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Advanced Melanoma Pipeline Outlook

Key Takeaways from the Advanced Melanoma Pipeline Report

In May 2025, Innovent Biologics (Suzhou) Co. Ltd. announced a phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects with Advanced Melanoma.
In May 2025, Iovance Biotherapeutics Inc. conducted a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
In May 2025, Anaveon AG organized a study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma. The study has 3 parts. Part 1 to evaluate ANV419 in monotherapy and Parts 2 and 3 to evaluate ANV419 in combination with anti-PD1 antibody or anti-CTLA4 antibody. Parts 2 and 3 were not initiated, as the prespecified efficacy criteria to graduate to Part 2 were not met at the interim analysis of Part 1.
In May 2025, iOnctura announced a study will enrol approximately 85 male and female patients aged over 18 years with advanced or metastatic UM, who have progressed following at least 1 prior immunotherapy treatment. The disease must be measurable (i.e., at least 1 measurable lesion) as per RECIST v1.1 by Computerised Tomography (CT) scan or Magnetic Resonance Imaging (MRI).
In May 2025, Iovance Biotherapeutics Inc. organized a study is the first-in-human (FIH) study of IOV-3001. IOV-3001 is an antibody interleukin-2 (IL-2) fusion protein in which a modified form of aldesleukin is incorporated into the antibody palivizumab. The Phase 1 portion will include 2 parts. Participants will receive IOV-3001 either before the Lifileucel regimen (Part 1) or after Lifileucel instead of aldesleukin (Part 2).
DelveInsight’s Advanced Melanoma Pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Advanced Melanoma treatment.
The leading Advanced Melanoma Companies such as Replimune, IO Biotech, BioNTech SE, Perspective Therapeutics, Agenus Inc., Dragonfly Therapeutics, Olatec Therapeutics LLC, Iovance Biotherapeutics, Inc., Novartis Pharmaceuticals, AstraZeneca, Exelixis, Transgene, Immunocore Ltd, BeiGene, Biocad, Shandong Boan Biotechnology Co., Ltd, Merck Sharp & Dohme LLC, Genentech, Inc., Aulos Bioscience, Inc., Multitude Therapeutics Inc., Amgen and others.
Promising Advanced Melanoma Pipeline Therapies such as Tebentafusp, T3011, IMC-F106C, Relatlimab, HLX208, DCB-BO1301, Pembrolizumab, and others.

Stay ahead with the most recent pipeline outlook for Advanced Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Melanoma Treatment Drugs

Advanced Melanoma Emerging Drugs Profile

Vusolimogene oderparepvec: Replimune

Vusolimogene oderparepvec (RP1) is based on a proprietary strain of herpes simplex virus and is genetically prepared with a fusogenic protein, GALV-GP R- and GM-CSF. The drug is intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. The unique formulation of RP1 includes a fusogenic protein, GALV-GP R-, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which work synergistically to maximize the therapeutic effects. RP1 has also been granted Priority review by the FDA in combination with Nivolumab to treat advanced melanoma. Currently, the drug is in Registration stage of its development for the treatment of Advanced Melanoma.

IO102-IO103: IO Biotech

IO102-IO103 combines our two wholly owned T-win® vaccines, IO102 and IO103, that are designed to activate and expand T cells specific for IDO1 and PD-L1, respectively. IDO1 and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. By combining IO102 and IO103, the product is intended to have a synergistic effect on cells in the TME that express IDO1 and/or PD-L1, leading to enhanced cell killing. In clinical trials, IO-102-IO-103 plus nivolumab achieved rapid, deep, and durable responses, even in patients with one or more poor prognostic factors (e.g., M1c, and high LDH), without increasing high-grade adverse events over anti-PD-1 therapy alone. The FDA has also granted Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody for patients with advanced melanoma. Currently, the drug is in Phase III stage of its development for the treatment of Advanced Melanoma.

BNT111: BioNTech SE

BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Advanced Melanoma.

[203Pb]VMT01: Perspective Therapeutics

VMT01 is a theranostic radiopharmaceutical developed by Perspective Therapeutics, specifically designed for the treatment of unresectable or metastatic melanoma. VMT01 is being developed to target and deliver 212Pb to tumor sites expressing MC1R, a protein that can be overexpressed in metastatic melanoma tumors. This compound targets the melanocortin 1 receptor (MC1R), which is often overexpressed in melanoma cells, enabling precise delivery of the alpha-emitting isotope 212Pb directly to tumor sites. The mechanism of action of VMT01 involves two distinct pathways: it induces direct cell killing through high-dose radiation while also promoting an immunogenic response that enhances immune-mediated tumor destruction at lower doses. This dual action not only aims to improve local tumor control but also stimulates systemic anti-tumor immunity. VMT01 has also received Fast Track Designation from the FDA. Currently, the drug is in Phase I/II stage of its development for the treatment of Advanced Melanoma.

Botensilimab: Agenus Inc.

Botensilimab is an investigational multifunctional anti-CTLA-4 immune activator (antibody) designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Currently, the drug is in Phase I stage of its development for the treatment of Advanced Melanoma.

The Advanced Melanoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Melanoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Melanoma Treatment.
Advanced Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Advanced Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Melanoma market

Explore groundbreaking therapies and clinical trials in the Advanced Melanoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Advanced Melanoma Drugs

Advanced Melanoma Companies

Replimune, IO Biotech, BioNTech SE, Perspective Therapeutics, Agenus Inc., Dragonfly Therapeutics, Olatec Therapeutics LLC, Iovance Biotherapeutics, Inc., Novartis Pharmaceuticals, AstraZeneca, Exelixis, Transgene, Immunocore Ltd, BeiGene, Biocad, Shandong Boan Biotechnology Co., Ltd, Merck Sharp & Dohme LLC, Genentech, Inc., Aulos Bioscience, Inc., Multitude Therapeutics Inc., Amgen and others.

Advanced Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Advanced Melanoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Advanced Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Advanced Melanoma Market Drivers and Barriers

Scope of the Advanced Melanoma Pipeline Report

Coverage- Global
Advanced Melanoma Companies- Replimune, IO Biotech, BioNTech SE, Perspective Therapeutics, Agenus Inc., Dragonfly Therapeutics, Olatec Therapeutics LLC, Iovance Biotherapeutics, Inc., Novartis Pharmaceuticals, AstraZeneca, Exelixis, Transgene, Immunocore Ltd, BeiGene, Biocad, Shandong Boan Biotechnology Co., Ltd, Merck Sharp & Dohme LLC, Genentech, Inc., Aulos Bioscience, Inc., Multitude Therapeutics Inc., Amgen and others.
Promising Advanced Melanoma Pipeline Therapies such as Tebentafusp, T3011, IMC-F106C, Relatlimab, HLX208, DCB-BO1301, Pembrolizumab, and others.
Advanced Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Advanced Melanoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Advanced Melanoma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Advanced Melanoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Melanoma– DelveInsight’s Analytical Perspective
Late Stage Products (Registration)
Vusolimogene oderparepvec: Replimune
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BNT111: BioNTech SE
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Botensilimab: Agenus Inc.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Advanced Melanoma Key Companies
Advanced Melanoma Key Products
Advanced Melanoma- Unmet Needs
Advanced Melanoma- Market Drivers and Barriers
Advanced Melanoma- Future Perspectives and Conclusion
Advanced Melanoma Analyst Views
Advanced Melanoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Melanoma Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

StaySaavy Launches Smart Platform to Unlock Hotel Booking Savings

StaySaavy helps travelers save money by automatically monitoring hotel bookings and rebooking when prices drop, ensuring they never overpay for hotel stays. The AI-powered tool offers seamless, zero-risk savings.

Travelers frustrated by volatile hotel prices now have a new tool to help them save – automatically. StaySaavy announces the launch of its smart travel savings platform that monitors hotel bookings and automatically rebooks them when prices drop, ensuring travelers always get the best possible deal.

In an era of dynamic hotel pricing, rates can fluctuate multiple times a day. Traditional booking methods often leave consumers overpaying or spending hours monitoring prices manually. StaySaavy solves this problem with an AI-powered solution that works behind the scenes – no effort required from the traveler.

“Our mission is to give travelers peace of mind knowing they’ll always get the best rate — even after they book,” said Daniel Lochner, Founder of StaySaavy. “Hotel pricing has become more complex post-pandemic, with significant last-minute shifts and reverse yield trends. StaySaavy is built to help modern travelers navigate this new landscape and save money effortlessly.”

The platform operates with zero risk: travelers keep their original booking confirmation while StaySaavy tracks price changes. If a lower price becomes available for the same room and dates, StaySaavy rebooks the reservation automatically, securing the savings for the user.

A full product demo is available at https://staysaavy.com/demo, showcasing exactly how StaySaavy works.

StaySaavy recently launched its pre-release campaign on Product Hunt, generating strong early interest and building a growing waitlist of eager travelers. The company plans to roll out public beta access in the coming months.

“As travelers seek more flexible, tech-driven booking experiences, StaySaavy meets this demand with smart automation and true value for consumers,” Lochner added.

Travelers and early users can join the waitlist now at www.staysaavy.com.

Media Contact
Company Name: StaySaavy
Contact Person: Daniel Lochner
Email: Send Email
City: NYC
State: NY
Country: United States
Website: https://staysaavy.com/

IBN Technologies’ Accounting & Bookkeeping Services Drive Efficiency and Compliance for Florida Businesses

“Accounting & Bookkeeping Services (USA)”

Florida businesses face rising costs and regulatory pressures, turning to accounting & bookkeeping services for expert financial management. IBN Technologies offers scalable virtual bookkeeping solutions customized to industries like healthcare and retail. Their services improve compliance, cash flow, and audit readiness while reducing expenses. With 25+ years of expertise, IBN enables firms to focus on growth through accurate, secure, and timely financial reporting.

Miami, Florida, 2 June 2025 – As financial complexity and regulatory requirements increase, businesses in Florida are turning more into accounting & bookkeeping services. Additionally, small and medium-sized businesses are increasingly outsourcing these services to gain access to expert knowledge and save on expenses. These services offer accurate, real-time financial management customized to industries including healthcare, retail, and construction, assisting companies in maintaining compliance, improving cash flow, and successfully preparing audits. Amidst mounting financial challenges, accounting and bookkeeping services are becoming more crucial for sustained expansion and operational efficiency.

Businesses like IBN Technologies are offering sophisticated, scalable virtual bookkeeping services and accounting solutions in response to the growing complexity of the financial industry. Businesses may concentrate on their core competencies while gaining instant financial insights and optimized processes by fusing innovative technology with in-depth industry expertise. Businesses may overcome regulatory obstacles, maximize resources, and make strategic decisions that support long-term stability and growth with the help of IBN Technologies’ specialist support and customized solutions.

Get 20 Free Hours of Expert Bookkeeping – Limited Services

Start Free Trail Now: https://www.ibntech.com/free-trial/

Accounting and Bookkeeping Challenges for Businesses in Florida

Florida’s small and mid-sized businesses confront increasing bookkeeping challenges, such as keeping accurate records, monitoring cash flows, and adhering to tax laws while keeping expenses under control. Due to challenges with scalability and compliance, finance personnel are frequently overworked.

Key issues encountered include:

Rising costs associated with in-house accounting staff and financial software

Difficulty in sourcing skilled local accounting professionals

Inconsistent financial reporting and delayed month-end close

Limited real-time access to financial data

Security concerns regarding sensitive financial information during exchanges

Many businesses rely on expert accounting bookkeeping service providers to address these obstacles. IBN Technologies supports a wide range of industries by delivering accurate, compliant, and cost-efficient financial services that enable companies to focus on growth.

Core Services Offered by IBN Technologies

IBN Technologies provides small and medium-sized businesses in Florida with complete accounting & bookkeeping services that are specifically designed to match their needs. They offer scalable solutions that improve operational effectiveness and financial accuracy, and they have over 25 years of industry expertise.

Key services include:

✅ Complete bookkeeping: from daily transactions to year-end reconciliations ensuring accurate financial records

✅ Accounts payable and receivable management: optimizing vendor payments and customer invoicing to enhance cash flow

✅ Tax filing assistance: guiding preparation and filing to ensure compliance and reduce liabilities

✅ Financial reporting and analysis: delivering insights through detailed reports to support strategic decision-making

✅ Cloud-based accounting platforms: offering secure, real-time financial management tools

✅ Industry-specific expertise: customized services for healthcare, retail, manufacturing, and professional sectors

Many small enterprises face complex financial hurdles requiring expert intervention. IBN Technologies offers a trusted bookkeeping service for small businesses, providing accurate, timely reporting and robust security through secure cloud platforms and real-time software. This approach enables clients to maintain compliance and make well-informed decisions.

IBN Technologies, a leading supplier of Florida’s outsourced accounting services, offers affordable, superior solutions that increase customer satisfaction. Real-time updates, smooth interaction with top financial systems, and dependable round-the-clock assistance are all features of their virtual accounting strategy. Supported by CPA-certified professionals who are knowledgeable with U.S. GAAP, they provide customized service plans and designate account managers to guarantee regular, proactive contact that is suited to the needs of every customer located in Florida.

Exclusive Business Advantages Special Trial Benefit: Receive 20 free hours of best bookkeeping software for small business services when you schedule your discovery session this week — availability is limited.

Major Cost Reduction: Cut operational expenses by up to 70% without compromising on service quality.

Proven Success and Client Impact

IBN Technologies’ commitment to accuracy and performance is reflected in the success stories of its Florida and nationwide clients:

A US-based retail startup lowered bookkeeping expenses by over 65% annually by adopting IBN Technologies’ remote bookkeeping model.

A healthcare provider accelerated month-end closings by 80% and enhanced reporting accuracy after outsourcing its bookkeeping to IBN Technologies.

These examples showcase IBN Technologies’ role as a trusted financial partner that delivers beyond routine transactional support.

Explore affordable, flexible options tailored to your business needs

View Pricing Now: https://www.ibntech.com/pricing/

Strengthening Your Financial Strategy with IBN Technologies

More businesses are opting to outsource bookkeeping for small business to enhance operations and preserve regulatory compliance as financial demands increase across Florida’s economic environment. IBN Technologies provides a professional accounting bookkeeping service that improves accuracy, cut costs, and eases the workload for internal teams. The business guarantees accurate financial reporting with real-time insight, catering to sectors including retail and healthcare.

It is anticipated that the trend toward outsourcing bookkeeping will continue to expand in the face of an uncertain market. To create scalable, strategic solutions, providers like IBN Technologies combine a wealth of experience with safe, cloud-based technology. In the face of growing financial complexity, outsourcing has evolved from a simple cost-cutting strategy to a conscious step toward resilience and sustainable growth.

Related Services:       

Outsourced Finance and Accounting: https://www.ibntech.com/finance-and-accounting-services/          

About IBN Technologies               

IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive efficiency and growth.           

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IBN Technologies’ Accounting & Bookkeeping Services Drive Efficiency and Compliance for Florida Businesses